로딩 중…
StockDiggingStockDigging

JW LIFESCIENCE CORPORATION

234080· KOSPI
₩11,360-0.35%
2026-06-19

Price Chart

JW LIFESCIENCE CORPORATION-6.73%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap179.88B KRW
Revenue252.72B KRW
Net Income7.03B KRW
Total Assets313.55B KRW
Net Assets218.75B KRW
Employees328
Value
P/E25.58x
P/B0.82x
PEG2.70x
P/S0.71x
EV/EBITDA27.44x
FCF Yield15.56%
Profitability
ROE3.21%
ROA2.24%
Op. Margin13.20%
Revenue Growth-7.44%
Earnings Growth9.49%
Financial Health
Debt Ratio43.34%
Total Debt40.34B KRW
FCF27.98B KRW
Cash8.86B KRW
Current Ratio1.09x
Net Debt/EBITDA4.09x
Dividend
Div. Yield4.83%
Div. Growth10.00%
Performance
1Y Return-6.73%
1M Return-2.82%
From 52W High-27.09%
1Y MDD-30.77%
Trading
Volume59,398 shares
Foreign Own.13.25%
Per Share
EPS1,843 KRW
BPS14,127 KRW

Company Info

CEO 노정열
Employees 328
Founded 1994
HQ 충청남도 당진시, KR

Established in 1994, this company produces and sells professional pharmaceutical infusions, including 3-Chamber nutritional infusions, which are manufactured by only a few companies. It has signed licensing-out and export contracts with global infusion manufacturer Baxter Corporation, becoming the first in Asia to obtain EU-GMP certification for its TPN production facility, recognizing its world-class production infrastructure. The HP Research Center is pursuing global growth through the development of non-PVC materials and the launch of TPN products, leveraging infusion-related technologies. JW Life Science is headquartered in Dangjin, Chungcheongnam-do.